This is therefore a comparing of the analyst recommendations, profitability, institutional ownership, risk, dividends, earnings and valuation in Mustang Bio Inc. (NASDAQ:MBIO) and Hepion Pharmaceuticals Inc. (NASDAQ:HEPA). The two are both Biotechnology companies that compete with one another.
Valuation and Earnings
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Mustang Bio Inc.||4||-3583.91||N/A||-1.24||0.00|
|Hepion Pharmaceuticals Inc.||3||0.00||N/A||-86.02||0.00|
We can see in table 1 the earnings per share, gross revenue and valuation of Mustang Bio Inc. and Hepion Pharmaceuticals Inc.
Table 2 provides Mustang Bio Inc. and Hepion Pharmaceuticals Inc.’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Mustang Bio Inc.||0.00%||0%||0%|
|Hepion Pharmaceuticals Inc.||0.00%||0%||-179.1%|
5.6 and 5.6 are the respective Current Ratio and a Quick Ratio of Mustang Bio Inc. Its rival Hepion Pharmaceuticals Inc.’s Current and Quick Ratios are 0.6 and 0.6 respectively. Mustang Bio Inc. has a better chance of clearing its pay short and long-term debts than Hepion Pharmaceuticals Inc.
In next table is shown Mustang Bio Inc. and Hepion Pharmaceuticals Inc.’s ratings and recommendations.
|Sell Ratings||Hold Ratings||Buy Ratings||Rating Score|
|Mustang Bio Inc.||0||0||1||3.00|
|Hepion Pharmaceuticals Inc.||0||0||0||0.00|
Mustang Bio Inc. has an average target price of $7, and a 58.01% upside potential.
Insider and Institutional Ownership
Roughly 7.1% of Mustang Bio Inc. shares are held by institutional investors while 57.5% of Hepion Pharmaceuticals Inc. are owned by institutional investors. Mustang Bio Inc.’s share held by insiders are 39.58%. Insiders Competitively, held 5.9% of Hepion Pharmaceuticals Inc. shares.
Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|Mustang Bio Inc.||-9.23%||-16.67%||-24.32%||-10.56%||-52.27%||3.74%|
|Hepion Pharmaceuticals Inc.||-2.31%||-26%||-73.51%||-84.34%||-94.14%||-85.01%|
For the past year Mustang Bio Inc. has 3.74% stronger performance while Hepion Pharmaceuticals Inc. has -85.01% weaker performance.
Mustang Bio Inc. beats on 6 of the 7 factors Hepion Pharmaceuticals Inc.
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel cancer immunotherapy products based on the chimeric antigen receptor engineered T cell technology. Its lead programs include MB-101 for the treatment of brain cancer that is in Phase I trials; and MB-102, a therapeutic agent in acute myeloid leukemia, which is in Phase I trials. The company was incorporated in 2015 and is based in New York, New York. Mustang Bio, Inc. is a subsidiary of Fortress Biotech, Inc.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.